B-CELL MATURATION ANTIGEN (BCMA) TARGETED THERAPIES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Size and Share Analysis: (2026 – 2033)

The B-cell Maturation Antigen (BCMA) Targeted Therapies Market is anticipated to grow at a CAGR of 18.2%, reaching USD 6.62 Bn in 2026 and expected to reach USD 21.34 Bn by 2033. The market growth is attributed to increasing cases of multiple myeloma, growing usage of CAR-T cell treatments and monoclonal antibodies, increased funding in cancer research, growing clinical pipeline of BCMA targeting drugs, and improvements in immunotherapy technology.

Key Takeaways from the B-cell Maturation Antigen (BCMA) Targeted Therapies Market Report

• CAR-T Cells segment is anticipated to hold the highest market share of 48.7% in 2026 due to their remarkable effectiveness in the treatment of relapse and refractory multiple myeloma and rising approval for advanced cell-based therapy. Multiple Myeloma is responsible for 1.8% of all newly diagnosed cancer patients in the U.S., as stated by the American Cancer Society.
• Multiple Myeloma segment is forecast to hold the highest market share accounting for 88.6% by 2026 owing to the higher prevalence rate of relapsed and refractory Multiple Myeloma and increased usage of immunotherapy treatment. The International Agency for Research on Cancer (IARC), about 187,000 new cases of multiple myelomas are diagnosed annually worldwide, driving the demand for BCMA therapies.
• North America is anticipated to hold the largest share in the global B-cell Maturation Antigen (BCMA) Targeted Therapies Market with a market share of around 45% in 2026 due to approvals of CAR-T therapy, presence of prominent biopharmaceutical companies, well-established healthcare infrastructure, and increased use of immunotherapy. As per the information provided by the National Cancer Institute (NCI), multiple myeloma is one of the most prevalent hematologic cancers in North America, and the increasing use of immunotherapy and cell therapy for treating cancers is expected to drive the market further.

Segmental Insights

Why is the CAR-T Cells Segment Acquiring the Largest Market Share?

CAR-T Cells segment is expected to hold the largest market share in terms of revenue in the B-cell Maturation Antigen (BCMA) Targeted Therapies Market, estimated to contribute about 48.7% to the overall B-cell Maturation Antigen (BCMA) Targeted Therapies Market value in 2026. The high market share of the CAR-T cells segment in the global market can be attributed to the effectiveness of CAR-T therapies in the treatment of multiple myeloma patients having few treatment options left due to their refractory nature.

In March 2025, Bristol Myers Squibb announced expanded manufacturing investments to support increasing global demand for BCMA-directed CAR-T cell therapies, aiming to improve treatment accessibility and reduce production turnaround times.

Which Indication Segment Dominates the Market?

Multiple Myeloma segment is estimated to hold the largest market share of 88.6% in 2026 owing to the growing number of patients suffering from recurrent and refractory multiple myeloma and rising utilization of advanced immunotherapies across the globe. BCMA has been proven to be an excellent treatment option for multiple myeloma patients due to its high expression rate among malignant plasma cells.

In February 2025, Johnson & Johnson reported positive Phase III clinical trial results for its BCMA-directed bispecific antibody therapy demonstrating significant progression-free survival benefits in relapsed multiple myeloma patients, strengthening the segment’s growth outlook.

Market Drivers

Rising Adoption of CAR-T Cell Therapies is Accelerating the B-cell Maturation Antigen (BCMA) Targeted Therapies Market

The rising utilization of CAR-T cell-based treatments has become a major factor contributing to the growth of the BCMA-targeted therapies market. The use of CAR-T cells directed against BCMA molecules has proved to be highly effective for relapsed and refractory cases of multiple myeloma, particularly when conventional therapies exhibit low success rates.

According to ASCO, Multiple myeloma continues to be one of the fastest-growing areas of hematologic cancers needing novel approaches to immunotherapy, with CAR T-cell therapy exhibiting responses of over 70% even among highly pre-treated patients in various clinical trials.

Increasing Prevalence of Multiple Myeloma is Driving Demand for BCMA-based Therapies

The rising global prevalence of multiple myeloma is increasing demand for BCMA-based therapies. This growth is driven by aging populations, increasing cancer incidence, and improved diagnostic rates. BCMA has become a significant biomarker and treatment target since it is abundantly expressed on malignant plasma cells, rendering it highly effective as a therapy target for multiple myeloma. Drug companies have invested significantly in the development of bispecific antibodies, antibody drug conjugates, and novel immune-based therapies for this condition.

According to the World Health Organization (WHO), cancer cases are projected to rise by more than 75% globally by 2050, increasing the need for advanced targeted oncology treatments.

Current Events and Their Impact on the B-cell Maturation Antigen (BCMA) Targeted Therapies Market

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Trends

• The rising utilization of CAR-T cells to treat relapsed and refractory multiple myeloma has contributed to enhanced outcomes, as well as growth in the market.
• The creation of bispecific antibodies will contribute towards achieving greater immunity as well as providing safer options for existing drugs.
• Pharmaceutical firms have increased their investment in cell therapy manufacturing plants to shorten manufacturing timeframes and make therapies more available.
• The rise in cases of diseases such as multiple myeloma has been driving the adoption of BCMA-based therapies. According to IARC, there are over 187,000 new cases of multiple myeloma each year globally, and this figure is increasing amongst the aging population.
• Regulatory approvals and expedited pathways to the market have created an incentive to develop new therapies that target BCMA. According to the FDA, there have been numerous approvals of new therapies for biologics and specific types of cancers over the years owing to advancements made in precision oncology.

Regional Insights

North America Dominates the B-cell Maturation Antigen (BCMA) Targeted Therapies Market Owing to Early Adoption of Advanced Immunotherapies

North America is projected to have a 45% share of the market in 2026, due to early approvals for BCMA-targeted CAR-T products, the presence of major biopharmaceutical companies, and high usage of immunotherapy. North America benefits from a well-established oncology research ecosystem, and good reimbursement policies and increased investments in personalized medicine and manufacturing facilities for cell therapy products. There will be continued increases in cases of hematological malignancies and especially multiple myeloma in North America.

According to the U.S. Food and Drug Administration (FDA) has approved multiple BCMA-targeted CAR-T and bispecific antibody therapies in recent years, strengthening the region’s leadership in advanced oncology therapeutics.

Asia Pacific B-cell Maturation Antigen (BCMA) Targeted Therapies Market Trends

Asia-Pacific is forecast to be the fastest-growing regional market for the period 2026-2033, driven by the high growth rate on account of higher cancer prevalence, improved healthcare facilities, increasing awareness about hematological cancers, and increased investment in biological and immunotherapy products. China, Japan, South Korea, and India are showing an increase in the adoption of precision therapy and a greater number of clinical trials with cell and gene therapies.

Besides this, biopharmaceutical companies across China, Japan, and India have started showing an interest in developing and manufacturing their own CAR-T therapy in order to make therapy more accessible while reducing the cost of therapy. In January 2025, Legend Biotech Corporation declared that it will increase its manufacturing and research capacity of cell therapy in Asia due to increasing demand for BCMA-based therapies.

Rising Adoption of Advanced Immunotherapies is Accelerating the B-cell Maturation Antigen (BCMA) Targeted Therapies Market Demand in United States

The United States B-cell Maturation Antigen (BCMA) Targeted Therapies Market is growing rapidly due to high prevalence of multiple myeloma, adoption of CAR-T cell therapy, and increased investments in precision oncology. United States provides a robust environment for clinical studies, regulatory framework, and high healthcare spending, which accelerates the development and launch of innovative immunotherapy drugs. Increase in cases of relapsed and refractory multiple myeloma patients is contributing to rising demand for BCMA targeted therapies.

In October 2025, GSK US announced that the FDA approved Blenrep (belantamab mafodotin-blmf), a BCMA-directed antibody-drug conjugate, in combination therapy for relapsed or refractory multiple myeloma. Clinical trial data demonstrated a 51% reduction in risk of death and significantly improved progression-free survival compared to conventional therapies

Japan B-cell Maturation Antigen (BCMA) Targeted Therapies Market Trends

The Japan B-cell Maturation Antigen (BCMA) Targeted Therapies Market is expected to increase during the forecast period owing to the aging population in the country, rising incidence rate of hematologic cancers, and the rising prevalence of novel and effective biological therapies and personalized cancer treatments. The population in Japan continues to be one of the most elderly populations in the world and hence generates demand for novel oncology products.

In February 2025, Takeda Pharmaceutical Company Limited announced continued investments in advanced oncology research and cell therapy collaborations aimed at improving treatment options for multiple myeloma patients in Japan.

Who are the Major Companies in B-cell Maturation Antigen (BCMA) Targeted Therapies Industry

Some of the major key players in B-cell Maturation Antigen (BCMA) Targeted Therapies are Celgene Corporation, GlaxoSmithKline plc., Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Industry News

• In March 2025, Bristol Myers Squibb announced expansion of its U.S. cell therapy manufacturing network to support increasing global demand for Abecma, the company’s BCMA-directed CAR-T therapy for relapsed or refractory multiple myeloma.
• In October 2025, GlaxoSmithKline plc (GSK) announced that the U.S. FDA approved Blenrep (belantamab mafodotin-blmf) combination therapy for treatment of relapsed or refractory multiple myeloma.

Market Report Scope

Analyst Opinion

• The B-cell Maturation Antigen (BCMA) targeted therapies market is experiencing strong momentum due to the growing burden of multiple myeloma and rising demand for advanced immunotherapies. Increasing relapse rates among patients are accelerating the adoption of CAR-T cells, bispecific antibodies, and antibody-drug conjugates globally.
• BCMA-targeted CAR-T therapies are transforming hematologic cancer treatment by delivering high response rates in heavily pretreated patients. Clinical studies have shown response rates exceeding 70% in relapsed or refractory multiple myeloma patients, highlighting the strong therapeutic potential of personalized cell therapies.
• Expansion of regulatory approvals and accelerated FDA pathways for oncology biologics are strengthening commercialization opportunities for BCMA therapies. Increasing investments by major pharmaceutical companies in manufacturing infrastructure and precision oncology are expected to improve therapy accessibility and long-term market penetration.
• Bispecific antibodies are emerging as a major growth opportunity within the market due to their off-the-shelf availability, reduced manufacturing complexity compared to autologous CAR-T therapies, and ability to engage immune cells more efficiently against cancer cells.
• Rising global cancer burden continues to create long-term growth opportunities for BCMA-targeted therapies. Global cancer cases are expected to increase significantly over the coming decades, supporting sustained demand for next-generation targeted oncology treatments.

Market Segmentation

• By Product Type (Revenue, USD Bn, 2021-2033)
  • Antibody Drug Conjugates
  • CAR- T cells
  • Bispecific Antibodies
• By Indication (Revenue, USD Bn, 2021-2033)
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
• By Region (Revenue, USD Bn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa
• Key Players
  • Celgene Corporation
  • GlaxoSmithKline plc.
  • Novartis AG
  • Juno Therapeutics
  • Gilead Sciences, Inc.
  • Amgen Inc.
  • Affimed N.V.
  • Poseida Therapeutics, Inc.
  • Autolus Ltd.

Sources

Primary Research Interviews

• Hematologists
• Oncologists specializing in multiple myeloma
• CAR-T cell therapy specialists
• Hospital oncology department administrators
• Biopharmaceutical company executives
• Clinical research organizations (CROs)
• Key opinion leaders (KOLs) in hematologic oncology and immunotherapy

Databases

• World Health Organization (WHO)
• National Cancer Institute (NCI)
• U.S. Food and Drug Administration (FDA)
• International Agency for Research on Cancer (IARC)
• National Institutes of Health (NIH)

Magazines

• Targeted Oncology
• Oncology Times
• Cancer Therapy Advisor
• PharmaVOICE

Journals

• Journal of Clinical Oncology
• Blood
• The Lancet Oncology
• Leukemia
• Clinical Cancer Research

Newspapers

• The Wall Street Journal
• Financial Times
• The New York Times
• Reuters Health News

Associations

• American Society of Clinical Oncology (ASCO)
• American Society of Hematology (ASH)
• European Hematology Association (EHA)
• International Myeloma Society (IMS)

Public Domain Sources

• Company Annual Reports and Investor Presentations
• Government Healthcare Agency Publications
• Clinical Trial Registries such as ClinicalTrials.gov
• FDA Approval Announcements and Regulatory Filings

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for Last 10 Years